Basic anthropometric characteristics and their relationship with the metabolism of saccharides in women with PCOS

Czech version

Authors: H. Šarapatková ¹; Y. Hrčková ²; R. Šarapatková ¹
Authors‘ workplace: Endokrinologická a interní ordinace, Olomouc, vedoucí MUDr. H. Šarapatková ¹; I. interní klinika Fakultní nemocnice Olomouc, doc. MUDr. M. Táborský, CSc., FESC, MBA ²
Published in: Ceska Gynekol 2011; 76(5): 343-348

Overview

Aim of study:
To determine basic anthropometric characteristics and their relationship with the metabolism of saccharides in women with PCOS in the Olomouc region.

Type of study:
Retrospective study of the results of 72 women with PCOS examined in the endocrinology clinic.

Material and method:
The study entailed the processing of data gained on the basis of examination of women sent to endocrinology clinic for examination in the years 2008–2010, who corresponded to the diagnostic criteria for PCOS according to the Rotterdam consensus. The obtained results of anthropometric measurement and characteristic saccharide metabolism were compared with a group of healthy women.

Results:
In groups of women of comparable age (PCOS average age 31.6, control group average age 31.4) the average BMI in women with PCOS was 26.76 kg.m^-2, the average waist measurement was 84.43 cm, the waist/hips ratio was 0.79, in the control group the average BMI was 24.73 kg.m^-2, the waist/hips ratio was 0.76, the differences between the two groups were not statistically significant

There was a statistically significant difference between women with PCOS and the healthy control group in C peptide values, even in comparable anthropometric parameters. Levels of fasting glycaemia and glycated haemoglobin were comparable.

Waist measurement, as a parameter for evaluating the level of visceral accumulation of fat in women with PCOS, was related to all monitored characteristics of saccharide metabolism (statistically significant correlation with fasting glycaemia, glycated haemoglobin and C peptide)

Unlike the waist measurement, the waist/hips ratio indicated a smaller percentage of women with abnormal obesity in both groups, in women with PCOS it correlated with fasting glycaemia and C peptide.

Conclusion:
On the basis of our results it can be stated that women with PCOS do not necessarily differ from the healthy control group in anthropometric parameters. However, with comparable age, BMI and level of visceral obesity, women with PCOS require a greater amount of insulin to maintain normoglycaemia than healthy women.

Key words:
polycystic ovary syndrome, body mass index, waist measurement, saccharide metabolism, C peptide.

Sources

1. Apridonidze, T., Essah, PA., Iuorno, MJ., Nestler, JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2005, 90, p. 1929.

2. Azziz, R., Woods, KS., Reyna, R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab, 2004, 89, p. 2745-2749.

3. Azziz, R. Epidemiology and pathogenesis of the polycystic ovary syndrome in adults UpDate, 2010.

4. Cascella, T., Palomba, S., De Sio, I., et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod, 2008, 23, p. 153-160.

5. Carmina, E., Legro, RS., Stamets, K., et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod, 2003, 18, p. 2289-2293.

6. Cibula, D., Cífková, R., Fanta, M., et al. Increased risk of non insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod, 2006, 15.

7. Cibula, D., Živný, J. Hyperandrogenní syndrom (syndrom polycystických vaječníků) – terminologie, historie, prevalence, etiologie, genetika. Čes Gynek, 2000, 5, s. 292-297.

8. Cibula, D., Živný, J. Hyperandrogenní syndrom (syndrom polycystických vaječníků) – diagnostická kritéria, diferenciální diagnostika, klinické příznaky a laboratorní nálezy (symptomatologie), pozdní rizika. Čes Gynek, 2000, 6, s. 424‑431.

9. Cibula, D. Is insulin resistance an essential component of PCOS?: The influence of confounding factors. Hum Reprod, 2004, 19, 4, p. 757-759.

10. DeUgarte, CM., Bartolucci, AA., Azziz, R. Prevalence of insulin resistence in the polycystic ovary syndrome using homeostasis model assessment. Fertil Steril, 2005, 83, p. 1454‑1460.

11. Dunaif, A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev, 1997, 18, p. 774.

12. Ehrmann, DA., Liljenquist, DR., Kasza, K., et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2006, 91, p. 48.

13. Ehrmann, DA. Polycystic ovary syndrome. N Engl J Med, 2005, 52, 3, p. 1223-1236.

14. Lankarani, M., Valizadeh, N., Heshmat, R., et al. Evalution of insulin resistence and metabolic syndrome in patients with polycysic ovary syndrome. Gyn End, 2009, 25, p. 504-507.

15. Legro, RS., Kunselman, AR., Dodson, WC., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab, 1999, 84, p. 165.

16. Ludwig, AK., Goharian, LG., Dietze, T., et al. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome. Fertil Steril, 2009, 92, p. 271-276.

17. Maciejewska-Jeske, M., Szczesna, A., Meczekaalski, B. Serum C – peptid concentration in overweight and obese women with polycystic ovary syndrome. Pol Merkur Lek, 2010, 29, p. 93-99.

18. Nestler, JE., Powers, LP., Matt, DW. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. JCEM, 1991, 72, p. 83-89.

19. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004, 19, p. 41-47.

20. Shaw, LJ., Merz, CNB., Azzis, R., et al. Postmenopausal women with a history og irregular menses and elevated androgen measurments at high risk for worsening cardiovascular event-free survival: results from NIH sponsored women ischemia syndrome evaluation. J Clin Endocrinol Metab, 2008, 93, p. 1276-1284.

21. Taponen, S., Martikainen, H., Jarvelin, MR., et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab. 2004, 89, p. 2114-2118.

22. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Azziz, R., Carmina, E., Didier, D., et al. (Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society) Fertil Steril, 2009, 91, 2, p. 456-488.

23. Vrbíková, J., Cífková, R., Jirkovská, A. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod, 2003, 5, p. 980-984.

24. Vrbíková, J., Vondra, K., Cibula, D., et al. Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod, 2005, 12, p. 3328-3332.

25. Vrbíková, J., Dvořáková, K., Grimmichova, T., et al. Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. Clin Chem Lab Med, 2007, 5, p. 639-644.

26. Vrbíková, J., Cibula, D., Dvořáková, K., et al. Insulin snsitivity in women with polycystic ovary syndrome. JCEM, 2004, 89, 6, p. 2942-2945.

27. Vrbíková, J., Hill, M., Bendlová, B., et al. Incretin levels in polycystic ovary syndrome. Eur J End, 2008, 159, p. 121-127.